Glucuronide prodrug strategies may enhance target specificity and reduce the toxicity of PARP inhibitors, but no clinical evaluation has been performed. We evaluated TSL-1502, a novel glucuronide prodrug of a PARP inhibitor, in a randomized, open-label, phase 2 study at 28 sites in China (NCT05420779). Eligible patient...
B. Lan, Faliang Xu, Tao Sun et al.· Signal Transduction and Targ...· 0 citations
Background Gastroenteropancreatic neuroendocrine tumors (GEP-NETs) display marked clinical heterogeneity, and conventional prognostic indicators such as TNM stage and Ki-67 index provide limited individualized risk discrimination. We aimed to develop and externally validate interpretable machine learning models for sur...
Yang-Wei Fan, Yu-Qian Yang, Ke Wang et al.· Frontiers in Oncology· 0 citations
We use cookies to run the site and, with your consent, for analytics and to show ads.
See our Cookie Policy.